^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vepugratinib (LY3866288)

    i
    Other names: LY3866288, LY-3866288, LY 3866288, LOXO435, LOXO-435, LOXO 435, LOX-24350, LOX 24350, LOX24350
    Associations

    News

    Trials
    Company:
    Eli Lilly
    Drug class:
    FGFR3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    17d
    J4G-MC-JZVD: A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) (2025-522855-25-00)
    P2/3, N=197, Not yet recruiting, Eli Lilly & Co.
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    5ms
    FORAGER-2: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (clinicaltrials.gov)
    P3, N=450, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    7ms
    Next-generation isoform-selective fibroblast growth factor receptor inhibitors. (PubMed, Trends Pharmacol Sci)
    Pan-FGFR-selective inhibitors (erdafitinib, pemigatinib, and futibatinib) have been developed in clinical practice...FGFR2-selective inhibitor lirafugratinib, FGFR3-selective inhibitors LOXO-435 and TYRA-300, FGFR2/3-selective inhibitor ABSK061, and FGFR4-selective inhibitors are in clinical development. Additionally, novel isoform-selective FGFR-targeting degraders, FGFR2b/FGFR3-selective antibodies, and de novo-designed 'c' isoform-selective proteins provide novel treatment strategies. This review provides an overview of the current FGFR-targeted therapeutics and limitations and evaluates next-generation inhibitor development to guide future research.
    Review • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4)
    |
    Balversa (erdafitinib) • Lytgobi (futibatinib) • Pemazyre (pemigatinib) • lirafugratinib (RLY-4008) • dabogratinib (TYRA-300) • lavengratinib (ABSK061) • vepugratinib (LY3866288)
    7ms
    FORAGER-2: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Eli Lilly and Company
    New P3 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    1year
    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (clinicaltrials.gov)
    P1, N=535, Recruiting, Eli Lilly and Company | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    1year
    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (clinicaltrials.gov)
    P1, N=535, Recruiting, Eli Lilly and Company | N=180 --> 535
    Enrollment change
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • vepugratinib (LY3866288)
    1year
    A Study of LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=15, Completed, Eli Lilly and Company | N=30 --> 15 | Recruiting --> Completed
    Trial completion • Enrollment change
    |
    vepugratinib (LY3866288)
    over1year
    A Study of [14C]-LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=15, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    vepugratinib (LY3866288)
    over1year
    A Study of [14C]-LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=16, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepugratinib (LY3866288)
    over1year
    A Study of LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=30, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vepugratinib (LY3866288)
    over1year
    A Study of [14C]-LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    vepugratinib (LY3866288)
    over1year
    A Study of LY3866288 in Healthy Participants (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    vepugratinib (LY3866288)